2006
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. 2006, 2010: cd001938. PMID: 17636690, PMCID: PMC10759270, DOI: 10.1002/14651858.cd001938.pub2.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAtrial FibrillationAtrial FlutterConfidence IntervalsHemorrhageHumansOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicStrokeThromboembolismConceptsAggregate odds ratioRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageOdds ratioDose warfarinMajor bleedsModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2001
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. Cochrane Database Of Systematic Reviews 2001, cd001938. PMID: 11279741, DOI: 10.1002/14651858.cd001938.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAtrial FibrillationAtrial FlutterConfidence IntervalsHemorrhageHumansOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicStrokeThromboembolismConceptsRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageDose warfarinMajor bleedsOdds ratioModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsAggregate odds ratioLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2000
Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials.
Miller M, McNamara R, Segal J, Kim N, Robinson K, Goodman S, Powe N, Bass E. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. The Journal Of Family Practice 2000, 49: 1033-46. PMID: 11093570.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Arrhythmia AgentsAtrial FibrillationEvidence-Based MedicineHumansMiddle AgedRandomized Controlled Trials as TopicConceptsAF conversionAtrial fibrillationSinus rhythmOdds ratioModerate evidenceMultiple antiarrhythmic agentsAdverse event ratesClinical trials databasesEfficacy of agentsAdverse event dataPharmacologic conversionAdverse eventsRandomized trialsTrials databasesCochrane CollaborationAntiarrhythmic agentsClinical trialsStudy qualityAgent efficacySuggestive evidenceEvent ratesFlecainideDisopyramideRelative efficacyStrong evidencePrevention of Thromboembolism in Atrial Fibrillation
Segal J, McNamara R, Miller M, Kim N, Goodman S, Powe N, Robinson K, Bass E, Center F. Prevention of Thromboembolism in Atrial Fibrillation. Journal Of General Internal Medicine 2000, 15: 56-67. PMID: 10632835, PMCID: PMC1495320, DOI: 10.1046/j.1525-1497.2000.04329.x.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAspirinAtrial FibrillationHumansOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicThromboembolismTreatment OutcomeWarfarinConceptsAtrial fibrillationMajor bleedsStroke preventionMajor hemorrhageCochrane Collaboration's CENTRAL databaseAdditional major bleedsMore major bleedingMore major bleedsMore major hemorrhagePrimary stroke preventionPrevention of thromboembolismRisk of hemorrhageTrials of drugsCentral databaseMajor bleedingYounger patientsPrimary preventionMean agePatient riskBaseline riskStroke rateLower riskAspirinPatientsModerate evidence